.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Cantor Fitzgerald
Express Scripts
Fuji
Daiichi Sankyo
Healthtrust
Medtronic
Chubb
Fish and Richardson
Federal Trade Commission

Generated: June 24, 2017

DrugPatentWatch Database Preview

AXUMIN Drug Profile

« Back to Dashboard

Which patents cover Axumin, and when can generic versions of Axumin launch?

Axumin is a drug marketed by Blue Earth and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-two patent family members in thirteen countries.

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this compound. Additional details are available on the fluciclovine f-18 profile page.

Summary for Tradename: AXUMIN

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list2
Patent Applications: see list8
Drug Prices:see details
DailyMed Link:AXUMIN at DailyMed

Pharmacology for Tradename: AXUMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Blue Earth
AXUMIN
fluciclovine f-18
SOLUTION;INTRAVENOUS208054-001May 27, 2016RXYesYes5,808,146► SubscribeY ► Subscribe
Blue Earth
AXUMIN
fluciclovine f-18
SOLUTION;INTRAVENOUS208054-001May 27, 2016RXYesYes9,387,266► Subscribe ► Subscribe
Blue Earth
AXUMIN
fluciclovine f-18
SOLUTION;INTRAVENOUS208054-001May 27, 2016RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: AXUMIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,817,776 Amino acid analogs for tumor imaging► Subscribe
9,381,259Precursor compound of radioactive halogen-labeled organic compound► Subscribe
8,758,724Unnatural amino acid radiolabeling precursor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AXUMIN

Country Document Number Estimated Expiration
Japan3992736► Subscribe
South Korea101643991► Subscribe
China101316812► Subscribe
BrazilPI0619213► Subscribe
World Intellectual Property Organization (WIPO)9717092► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Chubb
Healthtrust
Chinese Patent Office
Deloitte
UBS
Cerilliant
Cipla
Cantor Fitzgerald
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot